Company Overview and News
Shares of Genscript Biotech jumped 20 per cent after the company said the government had accepted its application for running clinical trials for its blood cancer treatment.
The director and buy-back activity slowed after surging for two straight weeks based on filings on the Hong Kong stock exchange from September 4 to 8, with 62 companies that recorded 276 purchases worth HK$262 million (US$33.5 million) versus 23 firms with 101 disposals worth HK$378 million.
* LTS was valued at 1.2 bln euros in 2014 deal (Adds details on LTS's business, rivals, potential buyers, owners' previous attempt to sell)
HONG KONG, 2er décembre 2016 /PRNewswire/ -- Luye Pharma Group Ltd. (2186.HK) est heureux d'annoncer la clôture de son acquisition des activités de systèmes transdermiques d'administration de médicaments (TDS) de la société suisse Acino. L'entreprise acquise est un leader mondial sur les marchés transdermiques de niche et elle va permettre d'améliorer les activités de développement de Luye dans la R et D, la fabrication, l'enregistrement international et la promotion commerciale de nouvelles formulations de produits conformément aux normes internationales, contribuant ainsi à ouvrir la voie de l'expansion de Luye sur les marchés internationaux.
HONGKONG, 1. Dezember 2016 /PRNewswire/ -- Die Luye Pharma Group Ltd. (2186.HK) hat die Übernahme des Geschäftsbereichs „Transdermale Therapeutische Systeme" (TTS) vom Schweizer Unternehmen Acino heute erfolgreich abgeschlossen. Der übernommene TTS-Bereich ist einer der weltweiten Marktführer im Nischenmarkt der Transdermalen Therapeutischen Systeme und ergänzt die Entwicklungsbemühungen von Luye Pharma in den Bereichen Forschung und Entwicklung, internationale Zulassung und Vertrieb.
HONG KONG, Dec. 1, 2016 /PRNewswire/ -- Luye Pharma Group Ltd. (2186.HK) is pleased to announce the completion of its acquisition of the transdermal drug delivery systems (TDS) business from Swiss company, Acino. The acquired business is a global leader in niche transdermal markets and will greatly enhance Luye's developmental efforts in R&D, manufacturing, international registration, and market promotion of new formulation products to international standards, thereby helping to pave the way for Luye's expansion into global markets.
Hang Seng futures are up 0.05 per cent to 22,815 in the pre-trade session Wednesday morning
RnRMarketResearch.com adds "Depression - Pipeline Review, H2 2016" to its store. The report provides an overview of the Depression's therapeutic pipeline with comprehensive information on the therapeutic development for Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
Columbia Pacific Management, an Asia healthcare provider based in Seattle, formed a 50/50 JV with Temasek to build healthcare facilities in China. Temasek is the sovereign wealth fund of Singapore. The JV, Columbia China, is the China division of Columbia Pacific. Columbia China already owns hospitals, clinics and senior living facilities in China, and it has more under construction. Temasek will invest $250 million into the JV for its 50% stake.
BioAtla LLC, a San Diego-Beijing biotech, entered a complicated deal with Pfizer (NYSE: PFE) that could be worth more than $1 billion to BioAtla (see story). The agreement combines BioAtla's Conditionally Active Biologic (CAB) antibodies with Pfizer's proprietary antibody drug conjugate (ADC) payloads. In addition, Pfizer has an exclusive option to develop and market BioAtla CAB antibodies that target CTLA4, an immuno-oncology target.
Luye Medical Group, an affiliate of Luye Pharma (HK: 2186), signed an MOU to bring international healthcare expertise to Chongqing. Luye will commit $300 million to bring up-to-date healthcare to a large healthcare complex being built by the Jiangbei District of Chongqing. Luye will run the complex while the district will provide the facilities. In 2016, Luye Medical closed a $688 million deal to acquire Healthe Care Australia, a chain of 17 Australian hospitals.
ReportnReports.com adds "Parkinson's Disease - Pipeline Review, H1 2016" market research report that provides an overview of the Parkinson's Disease's therapeutic pipeline with comprehensive information on the therapeutic development complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
Crown Bioscience International, a pre-clinical US-China CRO/CMO focused on cancer, recently applied to list on the Mainboard of Taiwan's GreTai Securities Market. At the recent BioTaiwan conference, there was considerable "buzz" about listing in Taiwan, even if, like CrownBio, the biopharma companies aren't located there. Singapore's Aslan Pharma, for example, is said to be considering Taiwan for its upcoming IPO, and JHL Biotech, a high profile Taiwan-China biosimilar company formed by US-biotech veterans, listed in Taiwan last year.
2017-12-11 - Wilton
2017-12-11 - Wilton
2017-12-03 - Wilton
2017-11-27 - Wilton